ReviewFrontiers in oncology2021

Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.

Henning Lauterbach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.